Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esophagitis prescription (traditional Chinese medicine compound) is a botanical therapeutic developed by The First Affiliated Hospital of Sun Yat-sen University for the treatment and prevention of acute radiation-induced esophagitis (ARIE). ARIE is a common and dose-limiting toxicity in patients receiving radiotherapy for thoracic malignancies, such as lung and esophageal cancers. This TCM compound is formulated based on traditional principles to clear heat, detoxify, and promote the healing of the esophageal mucosa. It is currently being evaluated in a Phase II randomized controlled trial (ChiCTR2400092981) to compare its efficacy against standard medical therapies in reducing the severity of radiation-induced mucosal damage and improving patient quality of life during cancer treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esophagitis prescription (traditional Chinese medicine compound).